Compare LODE & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | PLX |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.9M | 207.1M |
| IPO Year | 2004 | 1996 |
| Metric | LODE | PLX |
|---|---|---|
| Price | $1.78 | $2.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 840.6K |
| Earning Date | 11-02-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $1,553,796.00 | ★ $52,744,000.00 |
| Revenue This Year | $303.79 | $55.77 |
| Revenue Next Year | $410.04 | N/A |
| P/E Ratio | ★ N/A | $9.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $1.65 |
| 52 Week High | $4.98 | $3.19 |
| Indicator | LODE | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 23.75 | 42.21 |
| Support Level | N/A | $2.21 |
| Resistance Level | $3.32 | $2.75 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 11.29 | 7.41 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.